Rikoon Group LLC Has $4.22 Million Stake in Pfizer Inc. (PFE)
Rikoon Group LLC cut its holdings in Pfizer Inc. (NYSE:PFE) by 0.1% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 125,568 shares of the biopharmaceutical company’s stock after selling 83 shares during the period. Pfizer comprises approximately 1.9% of Rikoon Group LLC’s portfolio, making the stock its 10th biggest holding. Rikoon Group LLC’s holdings in Pfizer were worth $4,217,000 at the end of the most recent quarter.
Several other hedge funds have also added to or reduced their stakes in PFE. Altfest L J & Co. Inc. grew its holdings in Pfizer by 67.0% during the second quarter. Altfest L J & Co. Inc. now owns 107,278 shares of the biopharmaceutical company’s stock valued at $3,603,000 after purchasing an additional 43,024 shares during the period. HL Financial Services LLC grew its holdings in Pfizer by 1.1% during the second quarter. HL Financial Services LLC now owns 3,222,985 shares of the biopharmaceutical company’s stock valued at $108,260,000 after purchasing an additional 35,744 shares during the period. Sphera Funds Management LTD. bought a new position in Pfizer during the first quarter valued at $13,342,000. Searle & CO. grew its holdings in Pfizer by 92.7% during the first quarter. Searle & CO. now owns 80,052 shares of the biopharmaceutical company’s stock valued at $2,739,000 after purchasing an additional 38,500 shares during the period. Finally, Hartford Financial Management Inc. grew its holdings in Pfizer by 10.8% during the second quarter. Hartford Financial Management Inc. now owns 8,538 shares of the biopharmaceutical company’s stock valued at $286,000 after purchasing an additional 835 shares during the period. 69.89% of the stock is owned by institutional investors.
Pfizer Inc. (NYSE:PFE) traded up $0.68 during trading hours on Friday, hitting $37.14. The company’s stock had a trading volume of 12,524,254 shares, compared to its average volume of 19,888,109. The stock has a market capitalization of $218,400.30, a P/E ratio of 14.66, a P/E/G ratio of 2.59 and a beta of 1.01. Pfizer Inc. has a 12-month low of $30.90 and a 12-month high of $36.89. The company has a current ratio of 1.43, a quick ratio of 1.15 and a debt-to-equity ratio of 0.56.
Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, October 31st. The biopharmaceutical company reported $0.67 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.65 by $0.02. The firm had revenue of $13.17 billion for the quarter, compared to the consensus estimate of $13.17 billion. Pfizer had a return on equity of 25.41% and a net margin of 18.69%. The business’s quarterly revenue was up .9% on a year-over-year basis. During the same quarter in the prior year, the business posted $0.61 earnings per share. equities analysts forecast that Pfizer Inc. will post 2.59 earnings per share for the current year.
The firm also recently disclosed a quarterly dividend, which was paid on Friday, December 1st. Investors of record on Friday, November 10th were given a $0.32 dividend. The ex-dividend date of this dividend was Thursday, November 9th. This represents a $1.28 dividend on an annualized basis and a dividend yield of 3.45%. Pfizer’s dividend payout ratio (DPR) is presently 79.01%.
In related news, insider Alexander R. Mackenzie sold 14,700 shares of the stock in a transaction on Wednesday, November 1st. The stock was sold at an average price of $35.30, for a total value of $518,910.00. Following the sale, the insider now owns 117,432 shares in the company, valued at $4,145,349.60. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Alexander R. Mackenzie sold 7,350 shares of the stock in a transaction on Monday, October 2nd. The stock was sold at an average price of $35.65, for a total value of $262,027.50. Following the completion of the sale, the executive vice president now owns 117,432 shares in the company, valued at approximately $4,186,450.80. The disclosure for this sale can be found here. Company insiders own 0.06% of the company’s stock.
PFE has been the subject of several research reports. Sanford C. Bernstein set a $39.00 price objective on Pfizer and gave the company a “buy” rating in a report on Tuesday, September 19th. Barclays set a $38.00 price objective on Pfizer and gave the company a “buy” rating in a report on Wednesday, October 11th. BMO Capital Markets set a $37.00 price objective on Pfizer and gave the company a “buy” rating in a report on Tuesday, October 10th. ValuEngine raised Pfizer from a “hold” rating to a “buy” rating in a report on Friday, October 6th. Finally, Zacks Investment Research raised Pfizer from a “hold” rating to a “buy” rating and set a $40.00 price objective for the company in a report on Tuesday, October 3rd. Two analysts have rated the stock with a sell rating, six have issued a hold rating and thirteen have issued a buy rating to the company. The stock has an average rating of “Buy” and a consensus target price of $38.77.
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.